{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T06:10:08Z","timestamp":1742537408305,"version":"3.40.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,20]]},"DOI":"10.7759\/cureus.80927","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:37:33Z","timestamp":1742535453000},"source":"Crossref","is-referenced-by-count":0,"title":["Unveiling Histiocytic Sarcoma: A Rare Case of Diagnostic Complexity and Therapeutic Resistance"],"prefix":"10.7759","author":[{"given":"Abid Nawaz Khan","family":"Adil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bakht","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed S","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0349-RS","article-title":"Histiocytic sarcoma","volume":"144","author":"Hung YP","year":"2020","unstructured":"Hung YP, Qian X. Histiocytic sarcoma. Arch Pathol Lab Med. 2020, 144:650-4. 10.5858\/arpa.2018-0349-RS","journal-title":"Arch Pathol Lab Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21851","article-title":"Histiocytic sarcoma: new insights into FNA cytomorphology and molecular characteristics","volume":"125","author":"Hung YP","year":"2017","unstructured":"Hung YP, Lovitch SB, Qian X. Histiocytic sarcoma: new insights into FNA cytomorphology and molecular characteristics. Cancer Cytopathol. 2017, 125:604-14. 10.1002\/cncy.21851","journal-title":"Cancer Cytopathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000131541.95394.23","article-title":"Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy","volume":"28","author":"Hornick JL","year":"2004","unstructured":"Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004, 28:1133-44. 10.1097\/01.pas.0000131541.95394.23","journal-title":"Am J Surg Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127599","article-title":"Case report: targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis","volume":"14","author":"Zhao Y","year":"2023","unstructured":"Zhao Y, Deng Y, Jiang Y, et al.. Case report: targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis. Front Immunol. 2023, 14:1127599. 10.3389\/fimmu.2023.1127599","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01072-2","article-title":"Molecular mutations in histiocytosis: a comprehensive survey of genetic alterations","volume":"67","author":"Pai P","year":"2025","unstructured":"Pai P, Nirmal A, Mathias L, Jain S, Shetty MG, Sundara BK. Molecular mutations in histiocytosis: a comprehensive survey of genetic alterations. Mol Biotechnol. 2025, 67:438-55. 10.1007\/s12033-024-01072-2","journal-title":"Mol Biotechnol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2017.10.004","article-title":"Primary cutaneous histiocytic sarcoma: a report of five cases with primary cutaneous involvement and review of the literature","volume":"32","author":"Magro CM","year":"2018","unstructured":"Magro CM, Kazi N, Sisinger AE. Primary cutaneous histiocytic sarcoma: a report of five cases with primary cutaneous involvement and review of the literature. Ann Diagn Pathol. 2018, 32:56-62. 10.1016\/j.anndiagpath.2017.10.004","journal-title":"Ann Diagn Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20913","article-title":"Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant","volume":"82","author":"Abidi MH","year":"2007","unstructured":"Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol. 2007, 82:932-3. 10.1002\/ajh.20913","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.6603","article-title":"Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature","volume":"29","author":"Gergis U","year":"2011","unstructured":"Gergis U, Dax H, Ritchie E, Marcus R, Wissa U, Orazi A. Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature. J Clin Oncol. 2011, 29:e251-3. 10.1200\/JCO.2010.32.6603","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati A","year":"2018","unstructured":"Kommalapati A, Tella SH, Durkin M, Go RS, Goyal G. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2018, 131:265-8. 10.1182\/blood-2017-10-812495","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7098","article-title":"Challenges in the histopathologic diagnosis of histiocytic neoplasms","volume":"19","author":"Rech KL","year":"2021","unstructured":"Rech KL, He R. Challenges in the histopathologic diagnosis of histiocytic neoplasms. J Natl Compr Canc Netw. 2021, 19:1305-11. 10.6004\/jnccn.2021.7098","journal-title":"J Natl Compr Canc Netw"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.755893","article-title":"Case report: long-term response to radiotherapy combined with targeted therapy in histiocytic sarcoma harboring mutations in MAPK and PI3K\/AKT pathways","volume":"11","author":"Liu Z","year":"2021","unstructured":"Liu Z, Xiao Y, Liu X, et al.. Case report: long-term response to radiotherapy combined with targeted therapy in histiocytic sarcoma harboring mutations in MAPK and PI3K\/AKT pathways. Front Oncol. 2021, 11:755893. 10.3389\/fonc.2021.755893","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan C","year":"2020","unstructured":"Egan C, Nicolae A, Lack J, et al.. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica. 2020, 105:951-60. 10.3324\/haematol.2019.230375","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/352071-unveiling-histiocytic-sarcoma-a-rare-case-of-diagnostic-complexity-and-therapeutic-resistance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T05:37:35Z","timestamp":1742535455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/352071-unveiling-histiocytic-sarcoma-a-rare-case-of-diagnostic-complexity-and-therapeutic-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.80927","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}